TY - JOUR
T1 - Prediction of incident heart failure in established atherosclerotic cardiovascular disease
T2 - the SMART2-HF model
AU - Reitsma, Tessa H
AU - Lim, Carl-Emil
AU - Gynnild, Mari N
AU - Kaptoge, Stephen
AU - Lõo, Laura
AU - Holtrop, Joris
AU - Kuźma, Łukasz
AU - Pennells, Lisa
AU - Conrad, Nathalie
AU - Ueda, Peter
AU - Jernberg, Tomas
AU - Kurasz, Anna
AU - Keene, Spencer J
AU - Chilala, Chimweta
AU - Deo, Salil V
AU - Tillmann, Taavi
AU - Khunti, Kamlesh
AU - Piepoli, Massimo
AU - Rossello, Xavier
AU - Savarese, Gianluigi
AU - Dalen, Håvard
AU - Steg, Ph Gabriel
AU - Wood, Angela M
AU - Lees, Jennifer S
AU - Kavousi, Maryam
AU - McEvoy, John William
AU - de Boer, Rudolf A
AU - Andersson, Charlotte
AU - Bhatt, Deepak L
AU - Visseren, Frank L J
AU - Dorresteijn, Jannick A N
AU - Koudstaal, Stefan
AU - Di Angelantonio, Emanuele
AU - Hageman, Steven H J
N1 - Publisher Copyright:
© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2026/9/7
Y1 - 2026/9/7
N2 - Background and Aims: Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of developing heart failure (HF). However, incident HF is not part of the risk assessment of current guideline-recommended models. The aim of this study was to develop and externally validate the SMART2-HF model for prediction of incident HF in patients with ASCVD. Methods: SMART2-HF was developed in 7698 individuals with established ASCVD (coronary, cerebrovascular, or peripheral artery disease, or abdominal aortic aneurysm) but without prior HF from the UCC-SMART cohort. Cox proportional hazards models including sex-predictor interactions and with age as the time scale were derived to estimate the 10-year and lifetime risk of incident HF (hospitalization for HF or HF-related death), accounting for competing non-HF mortality. Predictors, limited to routinely available clinical characteristics, were aligned with the SMART2 risk model for recurrent cardiovascular (CV) risk in the same population. External validation was performed in 240 741 patients with ASCVD from six data sources: the Clinical Practice Research Datalink, the HUNT3 study, the SWEDEHEART Registry, the ASCVD-Particles cohort, the Estonian Biobank and the international REACH Registry. Results: During a median follow-up of 11.2 years (interquartile range 6.1–16.4 years), 1031 incident HF events (13%) occurred in the UCC-SMART cohort. In the external validation data sources, a total of 24 885 incident HF events (10%) occurred. The pooled C-statistic was .696 (95% confidence interval .674–.717), with consistent performance in subgroups by sex and type of ASCVD. Predicted risks matched observed incidence in external validation. Conclusions: The SMART2-HF model enables the prediction of incident HF in patients with ASCVD. Aligned with the guideline-recommended SMART2 model for recurrent CV risk, SMART2-HF can be used as a complementary tool in this population.
AB - Background and Aims: Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of developing heart failure (HF). However, incident HF is not part of the risk assessment of current guideline-recommended models. The aim of this study was to develop and externally validate the SMART2-HF model for prediction of incident HF in patients with ASCVD. Methods: SMART2-HF was developed in 7698 individuals with established ASCVD (coronary, cerebrovascular, or peripheral artery disease, or abdominal aortic aneurysm) but without prior HF from the UCC-SMART cohort. Cox proportional hazards models including sex-predictor interactions and with age as the time scale were derived to estimate the 10-year and lifetime risk of incident HF (hospitalization for HF or HF-related death), accounting for competing non-HF mortality. Predictors, limited to routinely available clinical characteristics, were aligned with the SMART2 risk model for recurrent cardiovascular (CV) risk in the same population. External validation was performed in 240 741 patients with ASCVD from six data sources: the Clinical Practice Research Datalink, the HUNT3 study, the SWEDEHEART Registry, the ASCVD-Particles cohort, the Estonian Biobank and the international REACH Registry. Results: During a median follow-up of 11.2 years (interquartile range 6.1–16.4 years), 1031 incident HF events (13%) occurred in the UCC-SMART cohort. In the external validation data sources, a total of 24 885 incident HF events (10%) occurred. The pooled C-statistic was .696 (95% confidence interval .674–.717), with consistent performance in subgroups by sex and type of ASCVD. Predicted risks matched observed incidence in external validation. Conclusions: The SMART2-HF model enables the prediction of incident HF in patients with ASCVD. Aligned with the guideline-recommended SMART2 model for recurrent CV risk, SMART2-HF can be used as a complementary tool in this population.
U2 - 10.1093/eurheartj/ehag153
DO - 10.1093/eurheartj/ehag153
M3 - Article
C2 - 41810961
SN - 0195-668X
VL - 47
SP - 4743
EP - 4757
JO - European heart journal
JF - European heart journal
IS - 34
ER -